Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26125336 | 1.00 | POLB (0.45) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26113415 | 0.90 | POLB (0.42) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26119053 | 0.89 | P2RY6 (0.49) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26124477 | 0.89 | P2RY6 (0.49) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL1096958 | 0.88 | P2RY6 (0.42) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26122705 | 0.88 | P2RY6 (0.42) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26122701 | 0.88 | P2RY6 (0.42) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26122578 | 0.88 | ABL1 (0.43) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL26123372 | 0.86 | P2RY6 (0.37) | POLBP2RY6P2RY14NT5EPTPN2 | |
| SCHEMBL26124617 | 0.86 | P2RY6 (0.37) | POLBP2RY6P2RY14NT5EPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | POLB 43/4885ABL1 3035/4885RIN1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.